(S)-2-methyl-N-(pent-4-en-1-yl)propane-2-sulfinamide | 1377321-98-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 亚磺酸及其衍生物
• 英文名称: (S)-2-methyl-N-(pent-4-en-1-yl)propane-2-sulfinamide
• 英文别名: (S)-2-methyl-N-(pent-4-en-1-ylidene)propane-2-sulfinamide；(+)-(Ss)-2-methyl-N-(pent-4-en-1-ylidene)propane-2-sulfinamide；(S)-2-methyl-N-pent-4-enylidenepropane-2-sulfinamide
• CAS: 1377321-98-6
• 化学式: C₉H₁₇NOS
• 分子量: 187.306
• InChiKey: HYTHKJWBSJYOCY-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.49
• 重原子数：
  12.0
• 可旋转键数：
  4.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  29.43
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  (S)-2-methyl-N-(pent-4-en-1-yl)propane-2-sulfinamide 在 1-羟基环己基苯基甲酮 、 水 、 臭氧 、 sodium t-butanolate 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 (S)-4-(((S)-tert-butylsulfinyl)amino)-4-(4-(trifluoromethyl)phenyl)butanoic acid
  参考文献：
  名称：

  用 1-羟基环己基苯基酮将伯醇和醛氧化成羧酸

  摘要：

  伯醇氧化成相应的羧酸是有机合成中基本且有用的反应之一。在本文中，我们报告了通过 1-羟基环己基苯基酮介导的氢化物转移反应将伯醇和醛氧化为酸的综合结果。在叔丁醇钠的强碱性条件下，室温氧化可耐受一系列官能团，包括脆弱的叔丁亚磺酰胺、胺、硫化物、烯烃和杂环，并提供良好至优异的产率。最重要的是，我们的氧化过程可以应用于在仲醇存在下将伯醇和醛化学选择性氧化为羧酸。

  DOI：

  10.1021/acs.joc.3c00096
• 作为产物：
  描述：

  4-戊烯-1-醇 在 草酰氯 、 copper(II) sulfate 、 二甲基亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 20.25h， 生成 (S)-2-methyl-N-(pent-4-en-1-yl)propane-2-sulfinamide
  参考文献：
  名称：

  调节针对不同适应症的脯氨酰寡肽酶抑制剂和成纤维细胞活化蛋白-α的抑制剂的选择性

  摘要：

  我们之前已经描述了几种不同化学系列的双环脯氨酰寡肽酶 (POP) 抑制剂作为神经退行性疾病的探针，在体外表现出纳摩尔活性和在纤维素中表现出亚微摩尔活性. 最近 POP 与肿瘤生长相关的同源成纤维细胞活化蛋白 α (FAP) 在癌症中的意义使我们考虑开发 POP/FAP 双抑制剂作为开发癌症治疗的有前景的策略。在这个阶段，我们考虑评估对 POP 抑制剂选择性优于 FAP 的要求，并评估能够开发选择性 POP 和双重 POP/FAP 抑制剂的分子平台。我们在此报告了一种新的双环支架的对接引导设计以及共价和非共价双环抑制剂的合成。首创 [4.3.0] 双环化合物的生物学评估证实，抑制剂活性需要反应基团或共价弹头。

  DOI：

  10.1016/j.ejmech.2022.114543

文献信息

• Stereoselective Addition of a Lithium Anion of 1,1-Diphenyl-2-aza-pentadiene to Sulfinimines: Application to the Synthesis of (−)-Epiquinamide
  作者：Manoj B. Uphade、Arava Amaranadha Reddy、Sopan P. Khandare、Kavirayani R. Prasad

  DOI：10.1021/acs.orglett.9b03507

  日期：2019.11.15

  of diphenylallylimine to nonracemic sulfinimines was investigated. It was found that the reaction with sulfinimines derived from aliphatic aldehydes afforded the products with excellent diastereoselectivity (>99:1), furnishing the product vicinal diamines in very good yields. Application of the formed product vicinal diamines was demonstrated in the total synthesis of the natural product (−)-epiquinamide

  研究了向非外消旋亚氨嘧啶中添加二苯基烯丙氨酸锂阴离子。发现与衍生自脂族醛的亚磺胺的反应提供了具有优异的非对映选择性（＞ 99∶1）的产物，以非常好的收率提供了产物邻位二胺。在天然产物（-）-表喹酰胺的全合成中证明了所形成的产物邻位二胺的应用。
• Asymmetric Total Synthesis of (+)-Merobatzelladine B
  作者：Nicholas R. Babij、John P. Wolfe

  DOI：10.1002/anie.201201001

  日期：2012.4.23

  The first total synthesis of (+)-merobatzelladine B was accomplished using an iterative sequence of stereoselective Pd-catalyzed alkene carboamination reactions for formation of two of the three rings. This represents a new strategy for the generation of polycyclic guanidine natural products, and provides access to compounds with a syn-relationship between the C6 H-atom and the C8 alkyl group.
• Optimized M24B Aminopeptidase Inhibitors for CARD8 Inflammasome Activation
  作者：Qifeng Chen、Alvin Wang、Dominic J. Covelli、Abir Bhattacharjee、Qinghui Wang、Elizabeth L. Orth-He、Sahana D. Rao、Hsin-Che Huang、Daniel P. Ball、Jeffrey C. Hsiao、Daniel A. Bachovchin

  DOI：10.1021/acs.jmedchem.2c01535

  日期：2023.2.23
• [EN] TRICYCLIC GPR65 MODULATORS<br/>[FR] MODULATEURS TRICYCLIQUES DE LA GPR65
  申请人：[en]PATHIOS THERAPEUTICS LIMITED

  公开号：WO2023067322A1

  公开（公告）日：2023-04-27

  One aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, (I) wherein: ring B is: a monocyclic aromatic group; or a monocyclic or bicyclic heteroaromatic group, each of which is optionally substituted by halo, CN, OH, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, hydroxycycloalkyl, O-cycloalkyl, alkoxy, haloalkoxy, heterocycloalkyl, O- heterocycloalkyl, aryl, heteroaryl, O-aryl, NHCO-alkenyl, NHCO-aryl, -(CH2)q-O-heteroaryl, CONH-aryl, aryloxy-alkyl, O-aralkyl, and CO2-alkyl, wherein said aryl, heteroaryl, heterocycloalkyl, O-cycloalkyl, NHCO-aryl, -(CH2)q-O-heteroaryl, CONH-aryl, aryloxy-alkyl, O-aralkyl, and O-aryl groups are each optionally further substituted by one or more groups independently selected from halo, alkyl, haloalkyl, alkoxy, NHCO-alkyl, NR13R13', SO2-alkyl, CN, hydroxyalkyl, CONR14R14', alkyl-NR15R15', heterocycloalkyl, alkyl-heterocycloalkyl, alkyl- cycloalkyl, aryl, (CH2)m-NHSO2-alkyl, CO2R16, alkoxy-alkyl, haloalkoxy, O-heterocycloalkyl, heteroaryl, alkoxy-alkoxy, and O-(CH2)p-cycloalkyl, where in the latter group, said cycloalkyl group is optionally further substituted by one or more halo, haloalkyl, alkyl or alkoxy groups; m is an integer from 0 to 3; p and q are each independently 0 to 3; Z is CR12; Y is CR10R10', wherein R10and R10'are each independently selected from H, F, alkyl, and haloalkyl; Raand Rbare each independently selected from H and alkyl; R6is selected from H, alkyl, cycloalkyl and hydroxyalkyl; R12is selected from H, alkyl, haloalkyl, halo, OH and O-alkyl; and R13, R13', R14, R14', R15, R15', and R16are each independently selected from H, alkyl, and alkoxyalkyl. Further aspects of the invention relate to compounds of formula (I) for use as a medicament, particularly in the field of immuno-oncology, immunology, and related applications.